Default object view. Click to create a custom template, Node ID: 108163, Object ID: 65179

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter r...

Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

No relation

Yes

No relation

No

01/05/2015 6:13 pm

No